RedHill Biopharma (NASDAQ:RDHL) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 4.9 %

Shares of NASDAQ:RDHL opened at $6.26 on Wednesday. The firm has a market cap of $8.02 million, a P/E ratio of -0.63 and a beta of 3.69. RedHill Biopharma has a 12-month low of $6.00 and a 12-month high of $34.00. The business has a fifty day simple moving average of $7.23 and a 200 day simple moving average of $75.96.

Institutional Trading of RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.